A landmark study published in Frontiers in Medicine by Albano, Paone, and Treglia delivers critical clinical validation for hospitals looking to adopt next-generation radioligand therapy. As the first-ever systematic review and meta-analysis of its kind, the study analyzed data from 80 metastatic castration-resistant prostate cancer (mCRPC) patients across 291 cycles. It conclusively proves that Terbium-161 (Tb-161) is not only highly effective but also exceptionally safe.
The clinical outcomes provide a compelling case for nuclear medicine departments. The pooled analysis demonstrated a remarkable 83.9% disease control rate and a 50.2% objective PSA response rate. Crucially, this high efficacy was maintained in late-stage patients who had previously failed conventional Lutetium-177 or Actinium-225 therapies, proving that Tb-161 can overcome established resistance pathways. Despite this powerful therapeutic effect, severe side effects were rare, confirming that the treatment fits safely and seamlessly into existing outpatient and inpatient hospital workflows.
This clinical advantage is driven by the unique physics of Terbium-161. By co-emitting medium-range beta particles and short-range Auger and conversion electrons, it delivers a massive, highly localized energy dose. This dual action successfully eradicates single cancer cells and micrometastases that traditional beta-only emitters often miss. Since Terbium-161 shares identical chelator chemistry with Lutetium-177, your hospital can easily adopt these protocols using your existing radiopharmacy infrastructure. Partner with TerThera today to secure a reliable, commercial-scale supply of high-purity Terbium-161 for your clinic.
